Insys Therapeutics to Present at the 2013 JMP Securities Healthcare Conference
(firmenpresse) - PHOENIX, AZ -- (Marketwired) -- 07/02/13 -- Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that develops and commercializes innovative supportive care products, today announced that it will participate in the 8th annual JMP Securities Healthcare Conference in New York, taking place on July 9-10, 2013.
President and Chief Executive Officer Michael L. Babich will present on Tuesday, July 9, 2013 at 1:30 p.m. ET. The presentation will be webcast live and available for replay at the Insys website .
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products, with a focus on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company has two marketed products including Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients. Insys markets Subsys through its incentive-based, cost-efficient commercial sales force. The company's lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol, which would be its second branded supportive care product, if approved.
Darryl S. Baker
Chief Financial Officer
Insys Therapeutics, Inc.
(602) 910-2617
John Woolford
Managing Director
Westwicke Partners, LLC
(443) 213-0506
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 02.07.2013 - 06:00 Uhr
Sprache: Deutsch
News-ID 1242014
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
PHOENIX, AZ
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 80 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Insys Therapeutics to Present at the 2013 JMP Securities Healthcare Conference
"
steht unter der journalistisch-redaktionellen Verantwortung von
Insys (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
